Company in its Board Meeting has approved financial results for period ended 31st March,2026
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Concord Drugs Limited reported standalone revenue of Rs 7,585 lakhs for FY26, up 105% from Rs 3,693 lakhs in FY25. Consolidated revenue was Rs 7,874 lakhs. Standalone PAT grew to Rs 104 lakhs from Rs 30 lakhs (up 251%), while consolidated PAT was Rs 106 lakhs versus Rs 34 lakhs. EPS improved to Rs 0.93 (standalone) and Rs 0.95 (consolidated). However, operating cash flow turned negative at Rs -737 lakhs (standalone) due to a sharp rise in trade receivables. The company also raised Rs 1,152 lakhs through equity share issuance and warrant allotments during the year. Auditors issued clean opinions but flagged emphasis of matter on Rs 4.14 crore of receivables outstanding over 2 years with no provision created.
Strong topline and bottom-line growth signals operational improvement, but negative operating cash flow and large outstanding receivables without provisions raise concerns about working capital management and potential future write-offs.